Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
709 (USA) · Dr. Novak
consented 2014-01-18
AEs
2
Serious
0
Dropout signal
–
Adverse events
moderate
assessed
Moderate OEDEMA PERIPHERAL — outcome: NOT RECOVERED/NOT RESOLVED; onset 2014-05-01 (study day 104.0); relationship: REMOTE
moderate
assessed
Moderate RASH — outcome: NOT RECOVERED/NOT RESOLVED; onset 2014-04-07 (study day 80.0); relationship: PROBABLE
Data queries
No data queries.